← Back

Shanghai Fudan Forward S&T Co Ltd

Shanghai Fudan Forward S&T Co., Ltd is involved in medical and health, digital economy, and high-tech businesses. It develops, produces, and sells computer systems, communication equipment, automation instruments, biotechnology products, and light source lighting, and also conducts import and export activities. The company researches, produces, and sells chemical raw materials, chemical pharmaceutical preparations, and traditional Chinese medicine, and exports fintech software to Japan. It also develops and manages high-tech parks, provides investment and consulting services, distributes car audio and high-end car care products, processes sheet metals, and develops health management systems. Its pharmaceutical focus includes specialized and specialty drugs, such as digestive system, nervous system, anti-tumor, and circulatory system drugs, as well as injectable glutathione, shuangyiping tablets, flutamide tablets, and isosorbide dinitrate tablets. Founded in 1984, the company is based in Shanghai, China.

Country
Price · split & dividend adjusted
News & notes moving 600624.CG
600624.CG2

ST Fuhua reports loss of 27.15 million yuan in first half of 2026

ST Fuhua disclosed its 2026 semi-annual report on August 26. In the first half, it achieved total operating revenue of 281 million yuan, down 14.01 percent year on year. Net loss attributable to the parent company was 27.15 million yuan, compared with a loss of 7.12 million yuan in the same period last year. Net loss after deducting non-recurring items was 29.49 million yuan, compared with a loss of 11.64 million yuan a year earlier. Net cash flow from operating activities was negative 22.63 million yuan, versus positive 431,300 yuan in the prior-year period. Basic loss per share was 0.04 yuan, and the weighted average return on equity was negative 6.40 percent. As of the end of the first half of 2026, the company's inventory book value was 382 million yuan, accounting for 93.91 percent of net assets, with inventory write-down provisions of 267 million yuan, representing a provision ratio of 41.13 percent. In addition, as of August 21, 2026, 10.19 percent of ST Fuhua's shares were pledged.
中国证券报·24dRead more →
600624.CG

ST Fuhua's first-half loss widens to 27.15 million yuan

ST Fuhua released its 2026 interim report. First-half operating revenue was 281 million yuan, down 14.0 percent year on year, while net profit attributable to the parent swung from a loss of 7.12 million yuan in the same period last year to a loss of 27.15 million yuan. Second-quarter operating revenue was 132 million yuan, down 20.5 percent year on year, with a net loss attributable to the parent of 16.21 million yuan. The company said pharmaceutical revenue declined under pressure from centralized procurement policies and falling prices, software revenue fell significantly due to a sharp drop in export sales to Japan, and the industrial park business remained basically stable.
财中社·25dRead more →
600624.CG

ST Fuhua shareholder Shangke Technology to have 7.8 million shares judicially auctioned

ST Fuhua announced that 7.8 million shares held by shareholder Shanghai Shangke Technology Investment Co., Ltd. will be judicially auctioned, accounting for 11.2706% of its holdings and 1.1482% of the company's total share capital. The Shanghai Third Intermediate People's Court ruled on April 2, 2025 to accept the bankruptcy liquidation case of Shangke Technology filed by Shanghai Haibang Asset Management Co., Ltd., and appointed the Shanghai Free Trade Pilot Zone branch of Daxin Certified Public Accountants as the administrator. The administrator will publicly auction the above shares on the JD.com bankruptcy liquidation platform in accordance with the law. In the first quarter of 2026, ST Fuhua achieved revenue of 149 million yuan and a net loss attributable to the parent company of 10.94 million yuan.
财中社·51dRead more →